Spyre UC drug posts 10-point RHI reduction
Spyre Therapeutics, Inc. (SYRE) reported positive Part A induction topline data from its Phase 2 SKYLINE trial of SPY003, an anti-IL-23 antibody for moderately-to-severely active ulcerative colitis.
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. (SYRE) reported positive Part A induction topline data from its Phase 2 SKYLINE trial of SPY003, an anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. SPY003 met the primary endpoint with a 10.0‑point reduction in Robarts Histopathology Index (RHI) at Week 12 (p<0.0001), alongside clinical remission and endoscopic improvement rates the company highlights as in line with the IL‑23 class.
The 10.0‑point RHI reduction was similar to previously reported reductions of 9.2 for SPY001 and 10.7 for SPY002, and the company states these are among the largest improvements seen in ulcerative colitis studies. In 44 SPY003 patients, 43% experienced treatment‑emergent adverse events, with 11% severe adverse events, 1 drug‑related adverse event, no drug‑related serious adverse events, and no deaths. Part B of SKYLINE, testing pairwise combinations of SPY001, SPY002 and SPY003, is enrolling, with topline induction data expected in 2027 and additional readouts from other IBD and immunology programs expected between late 2026 and early 2028.
Positive
- SPY003 met its primary endpoint in Phase 2 SKYLINE Part A, showing a 10.0‑point RHI reduction (p<0.0001) in moderately-to-severely active ulcerative colitis, which the company states is among the largest histologic improvements reported in UC trials.
- Across SPY001, SPY002 and SPY003, Spyre reports clinical proof-of-concept for all three IBD mechanisms, supporting its strategy to advance combination regimens in ulcerative colitis and other inflammatory bowel diseases.
- SPY003 showed a tolerability profile consistent with the IL‑23 class, with 19 of 44 patients (43%) experiencing treatment-emergent adverse events, only 1 drug-related adverse event (2%), no drug-related serious adverse events, and no deaths through Week 12.
Negative
- None.
Filing Explained
The disclosure moves SKYLINE from completed 12-week, open-label monotherapy testing in Part A to actively enrolling Part B, which will test two monotherapy dose levels and three pairwise combination arms in a randomized, placebo-controlled study; topline induction data are expected in 2027.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
RHI reduction with SPY003: 10.0-point reduction in Robarts Histopathology Index
Prior RHI reductions with SPY001 and SPY002: 9.2 and 10.7 points
Study population size (SPY003): 44 patients
+5 more
8 metrics
RHI reduction with SPY003
10.0-point reduction in Robarts Histopathology Index
Primary endpoint at Week 12 in Phase 2 SKYLINE Part A; p<0.0001
Prior RHI reductions with SPY001 and SPY002
9.2 and 10.7 points
RHI reductions observed with SPY001 and SPY002 in SKYLINE Part A
Study population size (SPY003)
44 patients
SPY003 SKYLINE Part A cohort through Week 12 (data cutoff July 27, 2026)
Treatment-emergent adverse events with SPY003
19 patients, 43%
Subjects with any TEAE during the induction period
Severe adverse events with SPY003
5 patients, 11%
Severe (Grade ≥ 3) adverse events reported in SPY003 cohort
Drug-related adverse events with SPY003
1 patient, 2%
Single drug-related adverse event (pruritus, Grade 1) that resolved without intervention
Serious adverse events with SPY003
3 patients, 7%
Serious adverse events deemed not drug-related; no drug-related SAEs or deaths
Advanced therapy–exposed patients
41%
Proportion of SKYLINE Part A SPY003 participants previously exposed to advanced therapy
Key Terms
Robarts Histopathology Index, modified Mayo Score, treatment-emergent adverse events, serious adverse events, +2 more
6 terms
Robarts Histopathology Index medical
"a 10.0-point reduction in Robarts Histopathology Index (RHI) score"
modified Mayo Score medical
"Secondary endpoints included clinical remission by modified Mayo Score of 20%"
A modified Mayo score is a simplified clinical measure used to gauge severity and improvement in ulcerative colitis by combining patient symptoms and a clinician’s assessment, typically leaving out the full endoscopic exam. For investors, it matters because changes in this score are often used as a trial endpoint to show a treatment’s benefit; clearer, faster improvements can speed regulatory decisions, affect drug valuation, and influence market confidence. An everyday analogy: it’s like a shorter vehicle inspection that focuses on visible problems rather than a full engine tear-down.
treatment-emergent adverse events medical
"There were 19 subjects with treatment-emergent adverse events (TEAEs)"
Events or symptoms that either appear for the first time or get worse after a patient starts a treatment; think of new or intensified side effects that show up once medicine or a medical device is used. Investors watch these closely because they affect whether a therapy can gain regulatory approval, be prescribed widely, or face legal and commercial setbacks—similar to how early customer complaints can sink a new product’s prospects.
serious adverse events medical
"Three serious adverse events (SAEs) were reported, deemed not drug-related"
Serious adverse events are significant problems or negative outcomes that occur during a medical treatment or clinical trial, such as severe side effects, hospitalizations, or life-threatening conditions. They matter to investors because such events can impact a company's reputation, lead to regulatory scrutiny, or delay the development of new products, ultimately affecting the company’s financial performance.
ulcerative colitis medical
"being investigated for the treatment of moderately-to-severely active ulcerative colitis"
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.
immunology and inflammation medical
"first- and best-in-class monotherapies and combinations in immunology and inflammation"
FAQ
What did Spyre Therapeutics (SYRE) announce about the SPY003 SKYLINE Part A trial?
Spyre announced that SPY003 met the primary endpoint in Phase 2 SKYLINE Part A for ulcerative colitis, achieving a 10.0‑point reduction in RHI at Week 12 (p<0.0001), with additional clinical remission and endoscopic improvement signals and a safety profile consistent with the IL‑23 class.
How strong was the efficacy signal for SPY003 in ulcerative colitis?
SPY003 produced a 10.0‑point reduction in Robarts Histopathology Index at Week 12 (p<0.0001). Spyre notes this is in line with prior reductions of 9.2 for SPY001 and 10.7 for SPY002, and describes these as among the largest improvements reported in UC studies.
What were the key safety findings for SPY003 reported by SYRE?
Among 44 SPY003 patients, 19 (43%) had treatment-emergent adverse events, 5 (11%) had severe events, there was 1 drug-related adverse event (2%), 3 (7%) serious adverse events deemed not drug-related, and no drug-related SAEs or deaths through Week 12.
How does the SPY003 result fit into Spyre Therapeutics’ broader IBD strategy?
With the SPY003 data, Spyre reports proof-of-concept across all three IBD mechanisms (α4β7, TL1A, IL‑23). This supports moving to SKYLINE Part B, which evaluates pairwise combinations (SPY120, SPY130, SPY230) and is currently enrolling patients with expected topline induction data in 2027.
What other clinical milestones has Spyre Therapeutics (SYRE) guided for?
Spyre highlights multiple upcoming readouts: SKYWAY in PsA/axSpA (SPY072) in 4Q 2026, SKYLINE Part B in ulcerative colitis in 2027, and SKYLIGHT in hidradenitis suppurativa (SPY072 + IL‑17A/F) in late 2027 or early 2028.
What was the patient population in the SPY003 SKYLINE Part A study?
The SPY003 cohort included patients with moderately-to-severely active ulcerative colitis, with 41% previously exposed to advanced therapies, a mean disease duration of 7.1 years, mean baseline RHI of 17.2 ± 8.3, mean modified Mayo Score of 6.9 ± 1.2, and 59% having an endoscopy score of 3.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2026
_______________________________________________________
(Exact name of Registrant as Specified in Its Charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: | ||
| Not Applicable | ||
(Former Name or Former Address, if Changed Since Last Report)
_______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
(Nasdaq Global Select Market) | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
SPY003 SKYLINE Part A Induction Topline Results
On September 8, 2026, Spyre Therapeutics, Inc. (“Spyre” or the “Company”) issued a press release announcing positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active ulcerative colitis (“UC”).
A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On September 8, 2026, the Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC.
SPY003 SKYLINE Part A Induction Topline Results
Efficacy: POC Established Across All Three Combination Components
Initial 12-week findings from SKYLINE Part A demonstrated that SPY003 met all key objectives. The study population consisted of 41% advanced therapy-exposed participants with a mean disease duration of 7.1 years, a mean baseline Robarts Histopathology Index (“RHI”) score of 17.2 ± 8.3 (SD), a mean modified Mayo Score (“mMS”) of 6.9 ± 1.2 (SD), and 59% of whom had a baseline endoscopy score of 3. SPY003 achieved the primary endpoint, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001), robust rates of clinical remission and endoscopic improvement, and a meaningful change in mMS. The 10.0-point reduction in RHI observed in participants receiving SPY003 is in line with the 9.2- and 10.7-point reductions observed in participants receiving SPY001 and SPY002, respectively, and all are among the largest improvements observed in UC trials to date.
| Endpoint (Week 12) | SPY003 | ||||
Change in RHI from baseline Primary endpoint | -10.0 (p<0.0001) | ||||
| Clinical remission rate | 20% | ||||
| Endoscopic improvement rate | 30% | ||||
| Change in modified Mayo Score | -3.5 | ||||
Safety: Well-Tolerated Profiles Across All Three Monotherapies Support Combination Development
As previously reported, SPY001 and SPY002 were each well tolerated in Part A, with safety profiles consistent with their respective classes, and no drug-related serious adverse events.
SPY003 was well tolerated with a safety profile consistent with the IL-23 class. There were 19 subjects with treatment-emergent adverse events (“TEAEs”) during the induction treatment period. Three serious adverse events (“SAEs”) were reported, deemed not drug-related. The most common adverse events (“AEs”) (occurring in ≥ 2 patients) were arthralgia (n=2), nasopharyngitis (n=2), and urinary tract infection (n=2).
| SPY003 | |||||
| Subjects with any AE (n, %) | 19 (43%) | ||||
| Severe (Grade ≥ 3) AE | 5 (11%)1 | ||||
| Drug-related AE | 1 (2%)2 | ||||
| AE leading to drug discontinuation | 0 | ||||
| SAE | 3 (7%)3 | ||||
| Drug-related SAE | 0 | ||||
| AEs of special interest | 0 | ||||
| Death | 0 | ||||
1Ulcerative colitis flare, intervertebral disc protrusion, anaemia, urinary tract infection, and acute cholecystitis, each in one subject; all deemed not drug-related.
2Pruritus (Grade 1) that resolved without intervention or treatment interruption.
3Hospitalization for ulcerative colitis flare, hemorrhoid thrombosis, and acute cholecystitis, each in one subject; all deemed not drug-related.
Data pertain to SPY003 (N=44) through Week 12 and data cut-off of July 27, 2026.
Next Steps
Clinical proof-of-concept across all three inflammatory bowel disease (“IBD”) programs strengthens the biological rationale for Spyre’s combination strategy and sets the stage for Part B of the SKYLINE trial, which is actively enrolling. Part B includes two dose levels of each monotherapy as well as three high-dose combination arms (SPY120, SPY130, and SPY230). Topline induction data from Part B are expected in 2027.
The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation (“I&I”), with multiple expected topline readouts over the next 12-18 months:
| Trial | Indication | Asset(s) | Expected timing | ||||||||
| SKYWAY | Psoriatic Arthritis (“PsA”), Axial Spondyloarthritis (“axSpA”) | SPY072 | 4Q 2026 | ||||||||
| SKYLINE Part B | UC | SPY001, SPY002, SPY003, SPY120, SPY130, SPY230 | 2027 | ||||||||
| SKYLIGHT | Hidradenitis Suppurativa (“HS”) | SPY072 + IL-17A/F | Late 2027 or early 2028 | ||||||||
Forward Looking Statements
This Current Report on Form 8-K contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K, other than statements of historical fact are forward-looking statements. These statements include, but are not limited to, statements regarding: the efficacy and safety of SPY001, SPY002 and SPY003 and their potential in other/a range of autoimmune diseases and as combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE Part B in UC and the potential further
development of these programs; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words “opportunity,” “potential,” “milestones,” “pipeline,” “strategy,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “might,” “plan,” “possible,” “predict,” “should,” “will,” “would,” “can,” “likely,” “aim,” and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This Current Report on Form 8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit Number | Description | |||||||
| 99.1 | Press release issued by Spyre Therapeutics, Inc. regarding Data, dated September 8, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPYRE THERAPEUTICS, INC. | |||||||||||
| Date: | September 8, 2026 | By: | /s/ Cameron Turtle | ||||||||
| Cameron Turtle Chief Executive Officer | |||||||||||
Exhibit 99.1
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score
Secondary endpoints included clinical remission by modified Mayo Score of 20% and
endoscopic improvement of 30%
SPY003 was well tolerated with a safety profile consistent with the IL-23 class
SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYLINE Part B evaluating pairwise combinations of these components is enrolling with topline induction data expected in 2027
WALTHAM, Mass., September 8, 2026 (GLOBE NEWSWIRE) – Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, a potential best-in-class anti-IL-23 being investigated for the treatment of moderately-to-severely active ulcerative colitis (UC). With these results, Spyre has now reported positive Part A data for all three mechanisms in its IBD portfolio (α4β7, TL1A, and IL-23), achieving clinical proof-of-concept for each component of the pairwise combinations being evaluated in Part B of the SKYLINE trial.
“SPY003 demonstrated a highly statistically significant 10-point reduction in RHI and meaningful clinical remission and endoscopic outcomes in line with the anti-IL-23 class,” said Deanna Nguyen, M.D., SVP of Clinical Development and SKYLINE study lead. “Combined with a well-tolerated safety profile and extended pharmacokinetics in alignment with the rest of our portfolio, these results position SPY003 as a potentially best-in-class combination component for patients with moderately-to-severely active UC.”
"With today’s SPY003 data building upon impressive SPY001 and SPY002 results, we have now delivered three potential best-in-class IBD readouts within a span of five months, demonstrating the quality and efficiency of our development organization and strategy,” said Cameron Turtle, DPhil, Chief Executive Officer of Spyre. “We engineered optimized antibodies against the best targets in IBD based on our thesis that better components will lead to better combinations. Each molecule has now demonstrated compelling monotherapy efficacy and safety data, and the combination cohorts are actively enrolling. We believe that these combinations have the potential to deliver an efficacy, safety, and dosing profile that
meaningfully surpasses today’s standard of care, and we are excited to unveil those data in 2027.”
Efficacy: POC Established Across All Three Combination Components
SKYLINE is a two-part induction and maintenance platform trial of SPY001, SPY002, SPY003, as well as pairwise combinations thereof (six investigational agents total) in patients with moderately-to-severely active ulcerative colitis. Part A is an open-label assessment of the safety and efficacy of a single dose level of each investigational monotherapy, and Part B is a randomized and placebo-controlled assessment of the safety and efficacy of investigational monotherapies (two dose levels) and combinations.
SPY003 is an extended half-life investigational antibody targeting IL-23, a cytokine implicated in chronic inflammation in IBD. Initial 12-week findings from SKYLINE Part A demonstrated that SPY003 met all key objectives. The study population consisted of 41% advanced therapy-exposed participants with a mean disease duration of 7.1 years, a mean baseline RHI score of 17.2 ± 8.3 (SD), a mean modified Mayo Score of 6.9 ± 1.2 (SD), and 59% of whom had a baseline endoscopy score of 3. SPY003 achieved the primary endpoint, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001), robust rates of clinical remission and endoscopic improvement, and a meaningful change in mMS. The 10.0-point reduction in RHI observed in participants receiving SPY003 is in line with the 9.2- and 10.7-point reductions observed in participants receiving SPY001 and SPY002, respectively, and all are among the largest improvements observed in UC trials to date.
| Endpoint (Week 12) | SPY003 | ||||
Change in RHI from baseline Primary endpoint | −10.0 (p<0.0001) | ||||
| Clinical remission rate | 20% | ||||
| Endoscopic improvement rate | 30% | ||||
| Change in modified Mayo Score | -3.5 | ||||
Safety: Well-Tolerated Profiles Across All Three Monotherapies Support Combination Development
As previously reported, SPY001 and SPY002 were each well tolerated in Part A, with safety profiles consistent with their respective classes, and no drug-related serious adverse events.
SPY003 was well tolerated with a safety profile consistent with the IL-23 class. There were 19 subjects with treatment-emergent adverse events (TEAEs) during the induction treatment period. Three serious adverse events (SAEs) were reported, deemed not drug-related. The most common adverse events (AEs) (occurring in ≥ 2 patients) were arthralgia (n=2), nasopharyngitis (n=2), and urinary tract infection (n=2).
| SPY003 | |||||
| Subjects with any AE (n, %) | 19 (43%) | ||||
| Severe (Grade ≥ 3) AE | 5 (11%)1 | ||||
| Drug-related AE | 1 (2%)2 | ||||
| AE leading to drug discontinuation | 0 | ||||
| SAE | 3 (7%)3 | ||||
| Drug-related SAE | 0 | ||||
| AEs of special interest | 0 | ||||
| Death | 0 | ||||
1Ulcerative colitis flare, intervertebral disc protrusion, anaemia, urinary tract infection, and acute cholecystitis, each in one subject; all deemed not drug-related.
2Pruritus (Grade 1) that resolved without intervention or treatment interruption.
3Hospitalization for ulcerative colitis flare, hemorrhoid thrombosis, and acute cholecystitis, each in one subject; all deemed not drug-related.
Data pertain to SPY003 (N=44) through Week 12 and data cut-off of July 27, 2026.
Next steps
Clinical proof-of-concept across all three IBD programs strengthens the biological rationale for Spyre’s combination strategy and sets the stage for Part B of the SKYLINE trial, which is actively enrolling. Part B includes two dose levels of each monotherapy as well as three high-dose combination arms (SPY120, SPY130, and SPY230), which the Company believes have the potential to deliver best-in-disease efficacy, safety, and treatment experience. Topline induction data from Part B are expected in 2027.
The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation, with multiple expected topline readouts over the next 12-18 months:
| Trial | Indication | Asset(s) | Expected timing | ||||||||
| SKYWAY | PsA, axSpA | SPY072 | 4Q 2026 | ||||||||
| SKYLINE Part B | UC | SPY001, SPY002, SPY003, SPY120, SPY130, SPY230 | 2027 | ||||||||
| SKYLIGHT | HS | SPY072 + IL-17A/F | Late 2027 or early 2028 | ||||||||
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
For more information, visit Spyre's website at www.spyre.com.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: Spyre’s ability to achieve the expected benefits or opportunities with respect to its product candidates, including its ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential best-in-class results for SPY001, SPY002 and SPY003; the potential for SPY003 to be a best-in-class IL-23 and combination component for patients with moderately-to-severely active UC; the potential for better components leading to better combinations; the potential for Spyre’s combinations to deliver an efficacy, safety, and dosing profile that meaningfully surpasses today’s standard of care; the potential for Spyre’s three high-dose combination arms to deliver best-in-disease efficacy, safety, and treatment experiences; Spyre’s ongoing and future clinical development activities, including Spyre’s plans for data readouts for the ongoing SKYLINE, SKYWAY and SKYLIGHT trials and timing thereof. The words "opportunity," "potential," "milestones," "pipeline," "strategy," "anticipate," "believe," "could," "estimate," "expect," "may," "might," "plan," "possible," "predict," "should," "will," "would," and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com
For Media:
Josie Butler, 1AB
josie@1abmedia.com